ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
SABCS 2024 – Lilly's PI3Kα push is no longer mutation-specific
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
ASH 2024 movers – moments of reckoning for menin and BTK
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
ASH 2024 – Astra sets the bar for Merck's Curon buy
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
